Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

Inclusion Criteria: * Female participants aged 18 years or older. * Documented persistent high-risk HPV infection for at least 6 continuous months, confirmed by consecutive HPV-DNA tests. * Absence of high-grade cervical lesions (≤ CIN1). * Availability of complete clinical records with evaluable HPV-DNA testing at baseline and follow-up. * Documented management with AHCC® supplementation alone, nonavalent HPV vaccination alone, or combined AHCC® supplementation and nonavalent HPV vaccination in routine clinical practice. * No prior excisional or ablative treatment of the cervix (including conization or LEEP). Exclusion Criteria: * History of cervical excisional or ablative treatment (including conization or LEEP). * Presence of high-grade cervical lesions (CIN2 or worse) or invasive cervical cancer. * Incomplete clinical documentation or missing HPV follow-up data. * Conditions known to significantly alter immune function, including ongoing immunosuppressive therapy, active autoimmune disease requiring systemic treatment, or documented immunodeficiency, when such information was available in medical records. * Prior systemic antiviral or immunomodulatory therapy specifically aimed at HPV clearance during the observation period.